Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00645281 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder.
A Phase 4 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 4
- Development phase
- 896
- Enrollment target
NCT00645281 is a Phase 4 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 896 participants.
The verdict
NCT00645281, a Phase 4 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 896 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of tolterodine in impacting the primary symptom or complaint of patients with OAB.
Interventions
- DRUG tolterodine extended release
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 896 participants |
| Start Date | 2004-03 |
| Est. Completion | 2005-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00645281
The ClinicalTrials.gov registry entry for NCT00645281 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 896 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tolterodine extended release is the first listed.
NCT00645281 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00645281 about?
NCT00645281 is a clinical study titled "A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder.". The purpose of this study is to evaluate the efficacy and safety of tolterodine in impacting the primary symptom or complaint of patients with OAB.
What is the current status of trial NCT00645281?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 896 participants. The study started on 2004-03. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00645281?
The interventions under investigation include: tolterodine extended release (DRUG).
Who is sponsoring clinical trial NCT00645281?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.